Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
October 30, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
September 25, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2023 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
August 30, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2023 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
August 07, 2023 08:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
August 03, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
- Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio - - Executed license agreement with Sangamo for prion disease treatment - -...
Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference
August 02, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
July 27, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2023 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...